FASLODEX in combination with abemaciclib showed 16.4 months of progression-free survival (PFS)
Second approval in three months expands treatment options for women with HR+, HER2- advanced breast cancer
AstraZeneca has a long history of community service and a strong commitment to making a meaningful difference for patients beyond our medicines.
In addition to our corporate efforts in the community, our Power of Us program empowers employees to give back in two ways: by providing paid time off to volunteer with nonprofit organizations of their choice, as well as by matching their personal charitable donations.
See our collective 2017 impactIf you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.